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ABSTRACT
Tumor metastasis refers to spread of a tumor from
site of its origin to distant organs and causes ma-
jority of cancer deaths. Although >30 metastasis
suppressor genes (MSGs) that negatively regulate
metastasis have been identified so far, two issues are
poorly understood: first, which MSGs oppose metas-
tasis in a tumor type, and second, which molecular
function of MSG controls metastasis. Herein, inte-
grative analyses of tumor-transcriptomes (n = 382),
survival data (n = 530) and lymph node metastases
(n = 100) in lung cancer patients identified non-
metastatic 2 (NME2) as a key MSG from a pool of
>30 metastasis suppressors. Subsequently, we gen-
erated a promoter-wide binding map for NME2 us-
ing chromatin immunoprecipitation with promoter
microarrays (ChIP-chip), and transcriptome profil-
ing. We discovered novel targets of NME2 which
are involved in focal adhesion signaling. Importantly,
we detected binding of NME2 in promoter of fo-
cal adhesion factor, vinculin. Reduced expression
of NME2 led to enhanced transcription of vinculin.
In comparison, NME1, a close homolog of NME2,
did not bind to vinculin promoter nor regulate its
expression. In line, enhanced metastasis of NME2-
depleted lung cancer cells was found in zebrafish
and nude mice tumor models. The metastatic po-
tential of NME2-depleted cells was remarkably di-
minished upon selective RNA-i-mediated silencing
of vinculin. Together, we demonstrate that reduced
NME2 levels lead to transcriptional de-repression of
vinculin and regulate lung cancer metastasis.
INTRODUCTION
More than 90% of cancer-related mortality results from
metastasis (1,2). Metastatic lesions are manifested in multi-
ple steps, including localized invasion and intravasation at
the primary tumor site, sustained survival in circulation, ex-
travasation at distant organ site(s) and colonization at the
new site (3,4). It is intriguing that despite the complexity, a
set of genes known as metastasis suppressor genes (MSGs)
can negatively regulate the metastatic process (5). Although
> 30 MSGs have been identified so far in various tumor
types (reviewed in (6,7,8)), two issues remain poorly under-
stood: first, the specificity of knownMSGs for a tumor type,
and second, how does reduced expression of MSG con-
tribute to metastasis.
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Primary tumors in lung metastasize to brain, bone,
contra-lateral lung, liver and kidney, and metastatic
growths are a major cause of cancer-related mortality in
men and women worldwide (9,10). In this report, we identi-
fied a keyMSG,NME2, from a pool of>30MSGs through
analysis of tumor transcriptomes, overall patient survival
data and lymph nodemetastases in lung cancer patients.We
investigated the molecular mechanisms of NME2 function
through genomic, cellular and molecular studies, including
model systems and validation in tumor/metastatic lymph
node tissue obtained from lung cancer patients. Findings
for the first time reveal that a MSG regulates a key focal
adhesion factor to control lung cancer cell dissemination.
MATERIALS AND METHODS
Cell lines and culture conditions
A549 cell line was obtained from the American Type Cul-
ture Collection. Cell line was authenticated by the cell bank
with short tandem repeat analysis. The cells were expanded
and stored according to the supplier’s instructions and used
within 6 months of recovery of frozen aliquots. The cells
weremaintained inDulbecco’smodifiedEaglemedium sup-
plemented with 10% fetal bovine serum at 37◦C in 5% CO2
environment. Details of generation of stable cell lines are
provided in the supplementary data.
ChIP-chip, peak generation, motif discovery, transcription
factor enrichment
ChIP assays were performed as per the protocol provided
by Upstate Biotechnology. Three independent experiments
were performed, cross-linked chromatin was immunopre-
cipitated, sequenase amplified, labeled, fragmented and
DNA hybridized to a set of Affymetrix 1.0 R oligonu-
cleotide microarrays. A 12-mer motif for NME2 was iden-
tified by Gibbs motif sampler at its default parameters. The
peak sequences were given as input into the Match tool
to scan for enriched PWMs listed in TRANSFAC profes-
sional.
Cancer cell extravasation assays in zebrafish
Control, vinculin-depleted, NME2-depleted and vinculin,
NME2 double knockdown A549 cells were trypsinized,
counted and labeled with Cell Tracker Orange CMTMR
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. The A549 cells were resuspended in
phosphate buffered saline containing DNase I and heparin,
and 50–200 cells were microinjected into the pericardium
of anesthetized 3 days-post-fertilization Tg(Fli-GFP) ze-
brafish. The zebrafish were put in 37◦C embryowater (water
supplementedwith salts formaintaining zebrafish embryos)
for 24 h following injection and imaged on a ZEISS LSM
780 confocal microscope using standard FITC and dsRed
filter sets.
Tail vein metastasis assays in nude mice
Approximately 1.5×106 A549 cells were injected into tail
vein permice; lungswere stained for human vimentin (Milli-
pore Inc.Massachusetts, USA) 8 weeks post-injection. Col-
lagen was stained by vWF antibody (Chemicon/Millipore
Inc. Massachusetts, USA). Confocal images were taken us-
ingLiecaTCSSP5 (Leica,Germany). The animal usage and
protocols involved were performed according to the guide-
lines approved by the Institutional Animal Ethical Commit-
tee of IICT and CCMB, Hyderabad.
Clinical annotation of tumor specimen
For analysis of expression of NME2 and VCL, we used
commercially available lung tumor samples (cDNA qRT
PCR arrays from Origene, Inc., USA). The primary lung
tumors and matched lymph node metastases for immuno-
histochemical (IHC) analysis of NME2 andVCLwere from
the archives of the Anatomic Pathology of the Second Uni-
versity of Naples, Italy (period from 1993 to date). The de-
tails on age, sex and pathology are provided as part of the
supplementary data.
IHC staining
Antibodies against vinculin were from Abcam, USA. For
Immunohistochemistry, primary lung tumor and autolo-
gous lymph node metastases were stained for NME2 (an-
tibody from Kamiya Biomedical Company, Seattle, USA)
and counterstained for haematoxylin.
Statistical analysis
In vitro cellular assays were done at least in triplicate, andP-
values were derived using student’s t test unless stated oth-
erwise. The error bars represent standard deviation unless
described otherwise. Statistical significance for immunos-
taining of NME2 in primary tumors and autologous lymph
node metastases was calculated using Pearson chi-square
test.
Additional description of Materials and Methods is pro-
vided in the supplementary data.
RESULTS
Integrative approaches to prioritize key MSGs associated
with malignant progression of lung tumors
To identify the key MSGs dictating metastasis of lung tu-
mors, we used a three-tiered approach: (i) identification of
MSGs which showed consistently reduced expression in ad-
vanced tumors relative to early stage tumors across inde-
pendent studies; (ii) analysis of association between expres-
sion levels of MSGs and overall patient survival and (iii)
whether MSG expression correlated to lymph node metas-
tasis in patients.
Transcriptomes from lung cancer patients (n= 382) were
grouped according to stage in each individual study: ad-
vanced (III and IV) versus early (I and II). Our analyses
revealed an interesting pattern: out of >30 MSGs (Supple-
mentary Table S1), 13 had reduced expression in at least one
study; only two MSGs, NME1 and MED23, had reduced
expression in two studies, and remarkably, only a single fac-
tor, NME2 (or NM23 H2), was found to have significant
reduced expression across all the four studies (Figure 1A–
E).
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Figure 1. Large-scale analyses of tumor transcriptomes identify keyMSG in lung cancermetastasis. Analysis of differential expression of>30MSGs across
four independent datasets (A–E); (A) representation of analysis from Curley et al. (expression project in Oncology (expO)), (B) Landi et al., (C) Takeuchi
et al. and (D) Raponi et al. The number of MSGs for which probes were found in individual study is also indicated next to the heat maps. Projections
from individual heat maps show changes in expression of MSGs; the right panel indicates subset of MSGs that showed reduced expression in advanced
stages relative to early stages; expression index: red: upregulation, blue: downregulation. (E) A heat map for 13 MSGs that showed reduced expression
in advanced tumor stages in at least one dataset examined; A fold change of −2, −3 and −4 corresponds to 50%, 66% and 75% decrease, respectively, in
expression level compared to early stage tumors; * = gene with reduced expression in at least two datasets; ** = gene with reduced expression in all four
datasets. Scale: fold change of expression.
Increased NME2 correlates with enhanced overall survival in
lung cancer patients
We next analyzed which of the three identified MSGs
(NME2, MED23 and NME1) correlated with overall pa-
tient survival. Using four independent datasets on overall
patient survival (n = 530), we first grouped patient samples
based on high versus low expression of individualMSG and
then evaluated association between MSG expression and
overall patient survival. Analysis of datasets from Takeuchi
et al. (n = 60) (11), Shedden et al. (n = 300) (12), To-
mida et al. (n = 60) (13) and Raponi et al. (n = 110) (Fig-
ure 2A) showed increased expression of NME2 correlated
with enhanced overall survival relative to low NME2 lev-
els (Figure 2A). Using similar analyses for both NME1 and
MED23 in all four datasets, we found that NME2 expres-
sion showed the best correlation with overall patient sur-
vival (Supplementary Figure S1A–D).
Next patient tumor DNA and tissues were examined for
expression of NME2 during progression from early to ad-
vanced stages, and lymph node metastases. Quantitative
real-time (qRT) PCR for NME2 showed significantly re-
duced transcript level in advanced stage tumor samples (n
= 44, ∼1.7-fold depletion; equivalent to 41% decrease, P
< 0.003; Figure 2B) confirming the trend observed in tu-
mor transcriptome meta-analyses. This result was further
supported by IHC analysis of NME2 in primary lung tu-
mors and matched lymph node metastases from same pa-
tients (n = 100; adenocarcinoma as well as squamous cell
carcinoma) where we found reduced NME2 level in metas-
tases compared to primary tumors (Figure 2C).
Transcriptome profile ofNME2-depleted cells correlates with
profiles obtained from advanced lung tumors and implicates
control of focal adhesion pathway
NME2 belongs to NME (non-metastatic 23/NM23) gene
family, which are the first discovered metastasis suppressors
(14). Among NMEmembers, NME1 and 2 have been most
studied in the context of metastasis suppression (15,16).
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Figure 2. Metastasis suppressor NME2 expression associates with overall survival and autologous lymph node metastasis in patients. Kaplan–Meier plot
was used to analyze relationship between NME2 transcript level and patient survival in data from (A) Takeuchi T et al.; n = 60, Shedden et al.; n = 300,
Tomida et al.; n = 60 and Raponi et al.; n = 110; hazard ratio for each analysis shown. Inset in all cases shows box plot of NME2 transcript level in the
two groups tested; statistical significance was calculated using student’s t test. (B) qRT PCR forNME2mRNA in 44 tumors grouped stage-wise from lung
cancer patients; 1.7-fold depletion corresponds to 41% decreased expression compared to early stage tumors. (C) Representative immunohistochemistry
images for NME2 in primary lung tumors and autologous lymph node metastases (left); quantitation of NME2 immunostaining (right panel, statistical
significance calculated by Pearson chi-square test).
However, only NME2 showed consistently reduced expres-
sion in advanced lung tumors (Figure 1A–E) and signifi-
cantly associated with overall patient survival (Figure 2A
and Supplementary Figure S1). Therefore, we focused on
NME2 in this study. Several studies have implicated NME2
as a regulator of genes implicated in cancer progression such
as c-MYC, PDGF-A, ITGAM (17,18,19) and telomerase
(20). Therefore, we asked whether the gene regulatory roles
of NME2 were important in the control of metastasis and
adopted a combinatorial strategy of (i) gene expression pro-
filing and (ii) chromatin immunoprecipitation coupled to
promoter microarray hybridization (ChIP-chip) to identify
novel targets ofNME2 and subsequently assessed their con-
tribution to metastasis (Figure 3A).
First, in order to understand whether lung
adenocarcinoma-derived A549 cells represent a possible
model for molecular studies, we probed the transcriptome
of A549 cells following NME2 depletion and assessed its
correlation with the gene expression profile of patient-
derived lung tumors. Investigation of >47,000 transcripts
following si-RNA-mediated NME2 depletion in A549 cells
revealed 296 genes as differentially regulated (124 genes
upregulated and 172 downregulated P < 0.005, Figure 3B,
left panel; 29 out of 30 genes were validated by qRT PCR,
False Discovery Rate (FDR) <5%; Supplementary Table
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Figure 3. NME2 depletion results in gene expression changes characteristic of tumors with metastatic proclivity. (A)A functional genomics framework for
exploring and validating functions of key metastasis suppressor, NME2; use of gene expression microarrays and chromatin immunoprecipitation coupled
to hybridization to promoter microarrays (ChIP-chip) to identify direct targets, and use of in vitro and in vivomodels for assessing contribution of targets to
cancer progression. (B)Gene expression changes on NME2 depletion in A549 lung adenocarcinoma cells: heat map of 296 genes showing relative change
in expression (1–3 are biological replicates); functional classification of the genes shows enriched biological pathways using Gene Ontology (GO)––top
four KEGG pathways are shown. Expression change after depletion of NME2 in A549 cells relates closely to advanced lung cancers. (C) Left panel:
heat map of normalized expression profile of 101 genes (126 probes) across 93 clinical datasets grouped stage-wise (P < 0.01); right panel: correlation of
relative fold change in expression between clinical samples and NME2-depleted A549 cells (correlation coefficient, P < 0.001). (D) Primary lung tumors
metastasize mainly to bones and brain; a framework to compare NME2-gene expression signature with previous organ-specific metastasis gene signatures.
(E) Expression profile of NME2-depleted A549 cells relates to primary lung adenocarcinomas with preference for metastasis to bone and brain; heat maps
represent relative fold changes in gene expression from Subramanian et al. (21; see the text), and Nguyen et al. (23; see the text) in left and right panel,
respectively (PC9-BrM3 and H2030-BrM3 are lung cancer cells with demonstrated metastatic proclivity to both brain and bone, respectively). (F) Focal
adhesion genes show deregulated expression in lung tumors with metastatic proclivity; GO of genes shared between NME2-depleted A549 cells and lung
cancer cells with metastatic preference for bone and brain.
S2). These 296 genes were designated as ‘NME2-responsive
genes’. Gene ontology (GO) analysis of NME2-responsive
genes using Genecodis 2 (21,22) identified focal adhesion
as the most significant pathway (Figure 3B, right panel).
Next, we compared the expression pattern of NME2-
responsive genes in A549 cells with lung cancer clinical
samples (n = 93) grouped as advanced (III and IV) versus
early stage (I and II). We used gene set enrichment analysis
(GSEA), a widely adopted computational method for de-
termination of statistical differences in gene expression be-
tween the chosen biological states (21). We found that 101
genes (126 probes) showed a pattern of differential expres-
sion in lung cancer clinical samples that significantly corre-
lated with the expression change noted in A549 cells follow-
ing depletion of NME2; 44 genes were upregulated and 57
genes downregulated in advanced compared to early stages
(Figure 3C).
As primary lung tumors frequently metastasize to brain
and bone (22), we checked whether gene expression pro-
gram of NME2-depleted cancer cells compared to tran-
scriptomes of brain and bone metastases (Figure 3D). We
observed significant similarity between transcriptomes of
NME2-depleted A549 cells and lung adenocarcinoma with
demonstrated preference for metastatic proclivity to bone
and brain (23,24) (Figure 3E). Importantly, the genes com-
mon to three studies showed significant enrichment of
focal adhesion pathway (Figure 3F). The analyses sup-
ported the findings made above (Figure 3B) that NME2-
mediated metastatic suppression might involve regulation
of key genes of focal adhesion pathway.
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Combinatorial analysis of promoter-wide binding and gene
expression reveals novel targets of NME2
We used ChIP-chip to identify NME2 binding sites across
promoters of the human genome and found a total of 553
binding peaks of NME2 at >2-fold binding enrichment (P
< 0.001, Figure 4A); 372 binding peaks out of 553 localized
on 346 unique promoters (typically within −7.5 kb to +2.5
kb of transcription start sites (TSS)) suggesting that some
promoters had more than one binding peak for NME2. We
found that 21 out of 22 promoters tested showed enrichment
in ChIP-PCR (FDR of <5%, Supplementary Figure S2A;
Supplementary Table S3). Using the Gibbs motif sampler
(25) we found a guanine-rich 12-mer sequencemotif present
in > 80% of NME2 ChIP-chip peaks, which is largely con-
sistent with earlier reports of NME2 as a purine-binding
factor (Supplementary Figure S2B) (17,18,19). Further-
more, using position weight matrices for transcription fac-
tor binding sites reported in TRANSFAC database (25)
we found binding sites of six transcription factors: PAX4,
PLZF, POU3F2, PAX6, OG2 and PPAR gamma to be sig-
nificantly enriched within NME2 binding peaks (Supple-
mentary Figure S2C).
As promoters differ in their chromatin architecture, it is
expected that not all promoters would show a change in
transcription. Therefore, we definedNME2-direct targets as
the genes, which changed their expression upon NME2 de-
pletion and also harbored NME2 binding peaks within re-
spective promoters (Figure 4B, left panel). Combined anal-
ysis of ChIP-chip peaks at an enrichment score of 1.2-fold
and transcriptome analysis significance (at P < 0.005) re-
sulted in identification of 64 genes (30 upregulated and 34
downregulated; Figure 4C, right panel) as NME2 direct
targets. Thus, while NME2 occupied 346 gene promoters,
64 of these promoters showed change in transcription on
NME2 depletion. Several of the target genes were validated
by ChIP-PCR (Supplementary Figure S2A) and qRT PCR
for expression (Supplementary Table S2). GO of NME2 di-
rect target genes showed distinct involvement in regulation
of transcription, nucleosome assembly, apoptosis and no-
tably cell adhesion (Supplementary Figure S2D;P< 0.05 in
all cases). Among genes related to cell adhesion, we found
vinculin (VCL), adenomatous polyposis coli (APC), Rho
related GTP binding protein B (RHOB) and connective tis-
sue growth factor (CTGF) as direct targets of NME2. To-
gether with NME2-responsive genes found to be enriched
for focal adhesion (Figure 3B and F), these genes act at dif-
ferent levels to control cell adhesion and signaling (26).
In order to understand the role played by NME2-
regulatory network in metastasis, we asked whether expres-
sion of the 64 NME2 target genes related to progression
of lung cancer. Analysis of lung cancer gene expression
datasets using GSEA revealed that 27 genes (33 probes),
which showed differential expression between advanced (III
and IV) versus early stages (I and II), were significantly
correlated with expression change in NME2-depleted A549
cells; 16 genes were upregulated and 11 downregulated (Fig-
ure 4D). This suggested that regulatory potential of NME2
is closely linked to progression into advanced cancers with
metastatic proclivity.
NME2 transcriptionally represses focal adhesion factor vin-
culin
Our analyses so far implicated regulation of focal adhe-
sion pathway by NME2; first, we found changes in tran-
script level of genes of focal adhesion pathway in response
to NME2 in our gene expression microarray analysis (Fig-
ure 3B for microarray and Figure 5A for representation),
and second, comparison of NME2-gene signature with pre-
vious metastasis signatures showed the highest enrichment
of focal adhesion pathway (Figure 3F). Interestingly, we
noted NME2 occupancy within the promoter of vinculin,
a key component of the focal adhesion pathway (27) (Fig-
ure 4C) and further tested the relationship between NME2
and vinculin. We found a 12-mer motif for NME2 located
262 bases upstream of vinculin TSS (Figure 5B, and Sup-
plementary Figure S2B for motif sequence). This was also
validated independently using ChIP for NME2 followed by
PCR with primers that flanked the motif (Figure 5B). Our
observations prompted us to investigate whether NME2
could directly bind to vinculin promoter. We employed a
direct binding assay where 12-mer oligonucleotide forming
the NME2-motif was used to check in vitro binding with
purified recombinant NME2 (a mutated version of the nu-
cleotide with key residues substituted served as control; de-
tails in supplementary materials and methods). Use of di-
rect binding assay clearly showed that purified NME2 pro-
tein binds to vinculin promoter, and the bindingwas sharply
diminished when NME2-motif was disrupted (Supplemen-
tary Figure S3). Interestingly, NME1, a homolog ofNME2,
did not show specific binding to vinculin promoter suggest-
ing a transcription regulatory role specific for NME2 (Sup-
plementary Figure S3).
Furthermore, we noted increased expression of vinculin
uponNME2 suppression fromanalysis ofmicroarrays (Fig-
ures 3B and 4C), and this was independently confirmed
at the mRNA and protein level (Supplementary Figure
S5; see Supplementary Figure S4 for stable depletion of
NME2; different shRNAs were used to generate stable cell
clones). In line, endogenous mRNA levels of vinculin de-
creased when NME2 was expressed in A549 cells (Supple-
mentary Figure S5). In addition, this was further confirmed
by luciferase reporter assays. The vinculin promoter har-
boring the NME2-motif showed increased promoter activ-
ity upon NME2-depletion in stable lines, conversely, the
vinculin promoter activity decreased upon NME2 expres-
sion (Figure 4C, and Supplementary Figure S4 for gener-
ation of A549 cells with stable depletion of NME2). We
also probed the contribution of kinase deficient mutant of
NME2 (19) in regulation of vinculin promoter activity. We
found that similar to wild-type NME2, kinase mutant also
suppressed activity of vinculin promoter (Supplementary
Figure S6A). This is consistent with our earlier observa-
tions where we had noted that kinase dead mutant did not
affect transcription (19). Furthermore, we investigated the
effect of NME1 on vinculin promoter activity in luciferase
assays; our results showed that NME1 did not significantly
alter activity of vinculin promoter (Supplementary Figure
S6B). In line, targeted silencing of NME1 did not lead to
any change in endogenousmRNA level of vinculin (Supple-
mentary Figure S6C andD). Together, these results demon-
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Figure 4. Promoter-wide location analysis identifies targets of NME2 involved in metastatic progression. (A) ChIP-chip for NME2 across promoters of
human genome: representative binding sites (peaks) and enrichment score on chromosome 8 in UCSC browser format. (B) Overlap of ChIP-chip and
expression microarray results identified genes with change in mRNA level as well as binding of NME2 to their respective promoters as direct targets of
NME2. (C) Position of NME2 binding site with respect to TSS and ChIP-chip enrichment score within the 64 direct targets of NME2 (left panel) and
the relative change (log ratio) in expression of the transcript as determined by microarrays on targeted depletion of NME2 in A549 cells (right panel).
(D) NME2-direct targets (36 probes representing 27 genes) show changes in expression across 93 lung carcinoma transcriptomes (grouped stage-wise)
concordant with changes in gene expression profile obtained in A549 cells; P = 0.003 (left panel); correlation of relative fold change in expression in
clinical samples versus NME2-depleted A549 cells (P < 0.0001 for correlation coefficient) (right panel).
strated that NME2 negatively regulates vinculin expression
through control of vinculin promoter activity, and this ac-
tivity is not exhibited by NME1.
Metastatic potential of NME2-depleted lung cancer cells is
attenuated in absence of vinculin in vivo
Wenext examined whetherNME2 depletion could promote
metastasis in vivo (in zebrafish and immunocompromised
mice), and whether its target, vinculin, was required for
NME2-mediated control of metastasis. Zebrafish is increas-
ingly becoming accepted as a particularly attractive model
system for studying metastasis (28). Indeed, because ze-
brafish embryos are optically transparent, these lend them-
selves well to study of engrafted cancer cells by confocal
microscopy (28). We performed a qualitative assay utiliz-
ing an in vivo cancer metastasis extravasation model (29) to
assess themetastatic potential ofNME2-depleted, vinculin-
depleted, andNME2 and vinculin double knockdownA549
cells in zebrafish (Supplementary Figure S7 for generation
of double knockdown cells). A549 cells were labeled with
a red tracker dye and microinjected into the pericardium
of 3 day post-fertilization (dpf) Tg(fli-GFP) zebrafish em-
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Figure 5. Focal adhesion pathway gene vinculin as a direct transcriptional target of metastasis suppressor NME2. (A) Representation of NME2-target
genes enriched in KEGG focal adhesion pathway; names are mentioned against highlighted boxes. Genes in blue color showed changes in mRNA level only
(indirect targets); in comparison, genes with asterisk (*) showed alteration in mRNA level and binding of NME2 to their promoter as well (direct targets).
(B) ChIP-PCR validation of NME2 occupancy of vinculin promoter: scheme showing NME2-motif within vinculin promoter; ChIP assay shows NME2
occupancy at the vinculin promoter; mock represents immunoprecipitation using non-specific isotypic IgG. (C) Over expression of NME2 represses (left
panel), and stable depletion of NME2 enhances vinculin promoter activity in a luciferase reporter assay (right panel); 3- and 50-fold depletion corresponds
to 66% and 98% decreased expression compared to control; all significance values: *P < 0.05, **P < 0.01; Student’s t test, error bars represent standard
deviation (SD).
bryos; pericardium represents the most relevant site of in-
jection as it enables cancer cells to directly enter into circu-
lation (29). After 24 h, we observed NME2-depleted cells
in the extravascular space, whereas control cells as well
as vinculin-depleted and NME2–vinculin double knock-
down cells remained in the intersegmental vessels (ISV)
(Figure 6A). Furthermore, we found NME2-depleted A549
cells actively extravasating from the ISV, but no similar ex-
travasation events were seen in zebrafish injected with the
control scrambled shRNA, vinculin-depleted or NME2–
vinculin double knockdown cells (Figure 6B). As the A549
cells with scrambled shRNA control did not show any ex-
travasation, it is clear that the present experimental design
did not detect any artifactualmovement of cells unrelated to
metastasis. Together, these findings demonstrate that while
NME2 depletion promoted metastasis, loss of vinculin di-
minished metastatic potential of NME2-depleted cells. We
next probed if NME2 depletion promoted metastatic dis-
semination of lung cancer cells in an experimental model
of metastasis in nude mice. We found 2-fold enhanced
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Figure 6. NME2 dictates extravasation of cancer cells through its target vinculin in zebrafish model of metastasis. Effect of knockdown of NME2 and
vinculin on extravasation of A549 cells in zebrafishmodel of metastasis (A–B); following injection of A549 cell clones (red) into pericardium of 3 dpf Tg(Fli-
GFP) zebrafish, the imaging was done 24 h later using a confocal microscope. In Tg(Fli-GFP) zebrafish, vasculature expresses GFP and appears green.
(A) Control A549 cells (red) are visible within the circulatory system (green) of zebrafish and have not extravasated. A549 cells with NME2 knockdown
(red) are extravasating from the circulatory system (green) and shown in extravascular space. Representative image of a control A549 cell in the tail ISV of
a zebrafish (top) and an image of an extravasating NME2-depleted A549 cell (bottom). (B) A549 cells with vinculin knockdown (red) and NME2 as well
as vinculin double knockdown (red) are visible within the circulatory system (green) of zebrafish and none have extravasated. Dpf: days-post-fertilization.
metastatic seeding by NME2-depleted cells relative to con-
trol A549 cells (Supplementary Figure S8A and B; n = 5
in each case, P < 0.05). These results supported the obser-
vations made in zebrafish and demonstrated that reduced
expression of NME2 promoted metastasis by A549 cells in
vivo.
Increased invasiveness and resistance to anoikis are fea-
tures of aggressive cancers (4,30). In line with our find-
ings, NME2-depleted A549 cells consistently displayed
enhanced invasiveness across extracellular matrix (ECM)
compared to control cells (Supplementary Figure S9A). As
expected, increased percentage of NME2-depleted A549
cells survived under anoikis-inducing conditions compared
to control cells (Supplementary Figure S9B). Furthermore,
similar to in vivo observations in zebrafish, targeted si-
lencing of vinculin in NME2-depleted A549 cells dimin-
ished their invasiveness across ECM (Supplementary Fig-
ure S9C andD). Furthermore, vinculin depletion inNME2-
depleted A549 cells perturbed downstream signaling as
evident by decrease in phospho-paxillin (Supplementary
Figure S9E). Collectively, these results demonstrate that
NME2-mediated regulation of vinculin favors a signaling
pathway that contributes to invasiveness and metastasis of
cancer cells.
Increase in NME2 correlates to reduced vinculin expression
in lung tumors
qRT PCR analysis showed significantly lower NME2 ex-
pression in advanced lung tumors (Figure 2B). Examina-
tion of vinculin transcripts in lung tumors showed the op-
posite trend: higher in advanced stages, clearly demonstrat-
ing an inverse relationship between NME2 and vinculin (n
= 29; P < 0.05; Figure 7A, right panel). Next, we probed
level of vinculin in primary tumors versus matched lymph
node metastases (derived from same patients, n = 100)
through IHC staining. This analysis showed increased vin-
culin expression in metastases relative to primary tumors
(Figure 7B). We compared the expression of NME2 and
vinculin in a pair-wise fashion in lymph node metastases
(n = 100) by assigning a score to intensity of IHC stain-
ing for each (Figure 7C). An inverse relationship between
NME2 and vinculin expression was clear from this analy-
sis; metastases were marked by low level of NME2 but high
level of vinculin, as noted inA549 cells. Importantly, to vali-
date our observation in different lung cancer lines, we found
increased vinculin levels upon NME2 knockdown in H157
cells, another non-small cell lung carcinoma line (Supple-
mentary Figure S10). Based on these findings, we propose a
model of metastasis control (Figure 7D) in which reduced
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Figure 7. Inverse relationships between vinculin and NME2 expression in lymph node metastases. (A) qRT PCR for NME2 and vinculin transcript in
stage-wise grouped tumors from lung cancer patients. Significance calculated by student’s t test. (B) Representative images of IHC staining for vinculin
in lung tumors (left) and quantitation of vinculin immunostaining (right). (C) Matched staining results for both NME2 and Vinculin in lymph node
metastases of 100 patients; inset shows staining pattern for NME2 and vinculin in three patients; strength of staining shown by color (top). (D)A proposed
model for anti-metastatic function of NME2 involving regulation of vinculin.
expression of NME2 in tumor cells perturbs focal adhesion
signaling by enhancing expression of vinculin. Increased
vinculin acts as a molecular trigger for altered cytoskeletal
rearrangement and enables metastasis.
DISCUSSION
Although a correlation between reduced expression of
NME members and micro-dissemination of lung tumors
has been noted (31,32) as well as an association between
decreased levels of NME2 transcripts with advanced stages
of lung tumors (33), the prognostic significance of NME2
in the context of lung cancer progression has been doubted
(34,35). Correspondingly, direct demonstration of NME2
action as a metastasis suppressor in lung cancer has been
lacking. Herein, our functional analyses in zebrafish and
nude mice showed that reduced expression of NME2 pro-
motes metastatic dissemination of lung cancer cells. Fur-
thermore, our results provide a molecular framework for
metastasis suppression by NME2, which involves regula-
tion of vinculin. Recent findings suggest that an enhanced
level of vinculin is necessary for generating focal adhe-
sion contacts at the cell periphery which impart contractile
forces for invasion through 3D matrix of extracellular pro-
teins (27). A signaling cascade downstream of vinculin in-
volving phosphorylation of cytoskeletal adaptors (paxillin)
and kinases, including focal adhesion kinase and myosin
light chain kinase, has been implicated in determination of
cellular invasiveness through acto-myosin cycling (27). In
line with these observations, we found that the metastatic
potential of NME2-depletedA549 cells in zebrafish (in vivo)
and invasiveness through basement membrane matrix (in
vitro) was diminished upon depletion of vinculin. This sup-
ports requirement of vinculin downstream of NME2 in reg-
ulation of cell invasion and metastasis.
Apart from vinculin, our findings show a large number
of NME2-specific association sites within promoters (346
in total). For example, previous studies have demonstrated
NME2-mediated regulation of c-myc (17,18,19). Recently,
NM23 occupancy on 10 promoters was observed (how-
ever, the study did not discriminate between NME1 and
NME2) (36). Despite these reports, the full regulatory po-
tential of NME2 has remained in doubt and unexplored be-
cause first, separate DNA binding and trans-activation do-
mains have not been characterized thus far for NME2, and
second, NME2 was shown to interact with single stranded
nucleotides rather non-specifically (please see the detailed
description in the supplementary data) (37,38). However,
our ChIP-chip results showed specific binding of NME2
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with target promoters revealing its transcriptional poten-
tial. In line, our direct binding assays demonstrated that
NME2 directly binds to its target promoters such as vin-
culin unlike its homolog, NME1. The magnitude of change
in VCL promoter activity (using luciferase reporter assays)
was similar in case of NME1 or NME2 expression (∼20%
increase or decrease, respectively). In contrast, on targeted
silencing we observed distinctly different results in case of
NME1. NME1 silencing resulted in no detectable (by real-
time PCR) difference in VCL expression (Supplementary
Figure S6C and D), whereas in case of NME2 silencing
there was >40% increase in VCL mRNA (Supplementary
Figure S5). Taken together with direct DNA binding results
showing specific binding of NME2, and not NME1 to the
vinculin promoter element (Supplementary Figure S3), we
inferred that NME1 does not bind to the vinculin promoter
and nor does it regulate vinculin.
Interestingly, recent observations suggest that NME2
may be part of transcriptional complexes and work in tan-
dem with other transcription factors such as OCT1 (39) or
Estrogen receptor beta (40). Notably, we observed associa-
tion of NME2 with histone 2B promoter in our ChIP-chip
data (Figure 4C). This is consistent with a previous finding
which also showedNME2 localization at theH2B promoter
as part of OCA-S transcriptional co-activator complex (39).
Thus, while the precise mechanism of NME2 association
with DNA may be currently unknown, it is clear from the
results obtained in this study that NME2 can influence the
gene regulatory program of cancer cells.
Our observations indicate that NME2-mediated gene ex-
pression may be crucial to metastasis. For example, we
found that NME2 associates with promoters of transcrip-
tion factors: ELK3, GLIS2, GTF2E2, c-MYC, MITF,
SLC2A4RG, ZNF238 and CHD9 (Figure 4C). Several of
these genes have been implicated in metastasis regulation
via control of Wnt/beta-catenin signaling and response to
hypoxia and tumor angiogenesis (41,42). NME2 depletion
led to upregulation of ELK3, which has been indepen-
dently shown to regulate HIF-alpha and enhance angiogen-
esis (41). Interestingly, GLIS2, another regulatory target of
NME2, has been demonstrated to function as a negative
regulator of Wnt/beta-catenin signaling pathway and was
crucial for lung cancer metastasis to brain (23,42).
To our knowledge, this is the first study of the regulatory
network of NME2, a key MSG with transcription-related
function. Using a combination of genomic approaches such
as ChIP-chip, we identify novel targets of NME2 and
demonstrate that NME2–vinculin signaling is important
for metastasis in vitro and in vivo. Therefore, therapeutic ap-
proaches that target NME2–vinculin signaling by either in-
creasing NME2 expression or decreasing vinculin level in
lung tumors could be of potential clinical significance. It is
noteworthy that several MSGs, such as BRMS1, CRSP3,
TXNIP, KDM1A and KLF17, apart from NME2 possess
transcription-related functions (Supplementary Table S1),
and therefore the integrative approaches used in the study
could be of interest to researchers working on these genes
as well.
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